601089 福元医药
交易中 03-24 13:01:18
资讯
新帖
简况
福元医药(601089.SH)：二十碳五烯酸乙酯软胶囊获得药品注册证书
智通财经 · 03-23 17:40
福元医药(601089.SH)：二十碳五烯酸乙酯软胶囊获得药品注册证书
【机构调研记录】银华基金调研福元医药
证券之星 · 03-17
【机构调研记录】银华基金调研福元医药
股市必读：福元医药（601089）3月16日披露最新机构调研信息
证券之星 · 03-17
股市必读：福元医药（601089）3月16日披露最新机构调研信息
福元医药：公司原料药业务目前以内部配套为主
证券日报 · 03-16
福元医药：公司原料药业务目前以内部配套为主
福元医药(601089.SH)：FY103注射液药物临床试验获批 目前国内外尚无同类型同靶点产品获批上市
智通财经 · 03-16
福元医药(601089.SH)：FY103注射液药物临床试验获批 目前国内外尚无同类型同靶点产品获批上市
福元医药(601089.SH)：双氯芬酸钠双释放肠溶胶囊获得药品注册证书
智通财经 · 03-16
福元医药(601089.SH)：双氯芬酸钠双释放肠溶胶囊获得药品注册证书
福元医药公布国际专利申请：“用于抑制INHBE基因表达的双链核糖核酸及其修饰物、缀合物和用途”
证券之星 · 03-16
福元医药公布国际专利申请：“用于抑制INHBE基因表达的双链核糖核酸及其修饰物、缀合物和用途”
每周股票复盘：福元医药（601089）FY101注射液I期临床效果达预期
证券之星 · 03-15
每周股票复盘：福元医药（601089）FY101注射液I期临床效果达预期
福元医药：太平洋证券、银河基金等多家机构于3月6日调研我司
证券之星 · 03-12
福元医药：太平洋证券、银河基金等多家机构于3月6日调研我司
福元医药(601089.SH)获得艾拉莫德化学原料药上市申请批准通知书
智通财经 · 03-02
福元医药(601089.SH)获得艾拉莫德化学原料药上市申请批准通知书
福元医药(601089.SH)参与国家组织集采药品协议期满品种接续采购拟中选
智通财经 · 02-11
福元医药(601089.SH)参与国家组织集采药品协议期满品种接续采购拟中选
福元医药(601089.SH)：盐酸溴己新口服溶液获得药品注册证书
智通财经 · 02-10
福元医药(601089.SH)：盐酸溴己新口服溶液获得药品注册证书
股市必读：福元医药（601089）2月6日披露最新机构调研信息
中金财经 · 02-09
股市必读：福元医药（601089）2月6日披露最新机构调研信息
【私募调研记录】彤源投资调研福元医药
证券之星 · 02-09
【私募调研记录】彤源投资调研福元医药
每周股票复盘：福元医药（601089）创新药FY101进入I期临床
证券之星 · 02-08
每周股票复盘：福元医药（601089）创新药FY101进入I期临床
福元医药：有知名机构彤源投资参与的多家机构于2月5日调研我司
证券之星 · 02-06
福元医药：有知名机构彤源投资参与的多家机构于2月5日调研我司
股市必读：福元医药（601089）2月2日收盘跌9.93%，主力净流出332.16万元
证券之星 · 02-03
股市必读：福元医药（601089）2月2日收盘跌9.93%，主力净流出332.16万元
每周股票复盘：福元医药（601089）FY101临床进展符合预期
证券之星 · 02-01
每周股票复盘：福元医药（601089）FY101临床进展符合预期
福元医药（601089）披露关于变更签字会计师的公告，1月29日股价下跌2.58%
证券之星 · 01-29
福元医药（601089）披露关于变更签字会计师的公告，1月29日股价下跌2.58%
福元医药：中金资管、淡水泉基金等多家机构于1月28日调研我司
证券之星 · 01-29
福元医药：中金资管、淡水泉基金等多家机构于1月28日调研我司
加载更多
公司概况
公司名称：
北京福元医药股份有限公司
所属行业：
医药制造业
上市日期：
2022-06-30
主营业务：
北京福元医药股份有限公司的主营业务是药品制剂及医疗器械的研发、生产和销售。公司的主要产品是心血管系统类、慢性肾病类、皮肤病类、消化系统类、糖尿病类、精神神经系统类、妇科类、一次性使用吸氧管。公司已入选北京医药产业跨越发展工程G20企业，荣列中国药品研发综合实力百强榜。
发行价格：
14.62
{"stockData":{"symbol":"601089","market":"SH","secType":"STK","nameCN":"福元医药","latestPrice":21.87,"timestamp":1774328478000,"preClose":21.49,"halted":0,"volume":1394082,"delay":0,"changeRate":0.0177,"floatShares":480000000,"shares":480000000,"eps":0.9648,"marketStatus":"交易中","change":0.38,"latestTime":"03-24 13:01:18","open":21.65,"high":22.05,"low":21.63,"amount":30404400,"amplitude":0.0195,"askPrice":21.88,"askSize":120,"bidPrice":21.86,"bidSize":4,"shortable":0,"etf":0,"ttmEps":0.9648,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1774335600000},"marketStatusCode":2,"adr":0,"adjPreClose":21.49,"symbolType":"stock","openAndCloseTimeList":[[1774315800000,1774323000000],[1774328400000,1774335600000]],"highLimit":23.64,"lowLimit":19.34,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":480000000,"isCdr":false,"pbRate":2.8,"roa":"--","peRate":22.66791,"roe":"10.35%","epsLYR":1.04,"committee":0.110119,"marketValue":10498000000,"turnoverRate":0.0029,"status":0,"floatMarketCap":10498000000},"requestUrl":"/m/hq/s/601089","defaultTab":"news","newsList":[{"id":"2621771190","title":"福元医药(601089.SH)：二十碳五烯酸乙酯软胶囊获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2621771190","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621771190?lang=zh_cn&edition=full","pubTime":"2026-03-23 17:40","pubTimestamp":1774258819,"startTime":"0","endTime":"0","summary":"智通财经APP讯，福元医药(601089.SH)发布公告，近日，公司全资子公司浙江爱生药业有限公司(以下简称“浙江爱生”)收到了国家药品监督管理局(以下简称“国家药监局”)颁发的二十碳五烯酸乙酯软胶囊(规格：1.0g)《药品注册证书》(证书编号：2026S00777)，批准该药品生产。根据米内网数据显示，2025年中国三大终端六大市场二十碳五烯酸乙酯软胶囊的销售额约为4,357万元，其中城市公立医院和县级公立医院销售额为427万元，城市社区中心和乡镇卫生院销售额为3万元，城市实体药店和网上药店销售额为3,927万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417430.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"福元医药(601089.SH)：二十碳五烯酸乙酯软胶囊获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601089","BK0239"],"gpt_icon":0},{"id":"2620413304","title":"【机构调研记录】银华基金调研福元医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2620413304","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620413304?lang=zh_cn&edition=full","pubTime":"2026-03-17 08:10","pubTimestamp":1773706245,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及3月16日披露的机构调研信息，银华基金近期对1家上市公司进行了调研，相关名单如下：1）福元医药 调研纪要：公司FY101注射液正进行I期临床试验，效果达预期；FY103处于IND阶段，肝外递送技术已有布局但处于早期阶段。银华基金成立于2001年，截至目前，资产管理规模6491.57亿元，排名22/212；资产管理规模3137.41亿元，排名20/212；管理公募基金数405只，排名18/212；旗下公募基金经理78人，排名12/212。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031700006861.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","601089"],"gpt_icon":0},{"id":"2620498131","title":"股市必读：福元医药（601089）3月16日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2620498131","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620498131?lang=zh_cn&edition=full","pubTime":"2026-03-17 01:33","pubTimestamp":1773682390,"startTime":"0","endTime":"0","summary":"截至2026年3月16日收盘，福元医药报收于23.17元，上涨0.65%，换手率0.52%，成交量2.51万手，成交额5778.3万元。来自公司公告汇总：公司自主研发的FY103注射液获准开展临床试验，为化学药品1类创新药，适应症为高血压。FY103注射液处于IND阶段，已获得《药物临床试验批准通知书》，后续将按信息披露要求及时公告。公司公告汇总北京福元医药股份有限公司收到国家药品监督管理局核准签发的FY103注射液《药物临床试验批准通知书》，同意开展临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031700001278.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","601089"],"gpt_icon":0},{"id":"2619463559","title":"福元医药：公司原料药业务目前以内部配套为主","url":"https://stock-news.laohu8.com/highlight/detail?id=2619463559","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619463559?lang=zh_cn&edition=full","pubTime":"2026-03-16 20:06","pubTimestamp":1773662760,"startTime":"0","endTime":"0","summary":"证券日报网3月16日讯 ，福元医药在接受调研者提问时表示，公司原料药业务目前以内部配套为主，围绕“原料药+制剂”一体化进行布局，旨在提升产业链协同效应和盈利空间。后续公司将根据主业发展需要，持续发挥原料药业务的支撑作用。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-16/doc-inhrevaq9848921.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-16/doc-inhrevaq9848921.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["601089","BK0239"],"gpt_icon":0},{"id":"2619459308","title":"福元医药(601089.SH)：FY103注射液药物临床试验获批 目前国内外尚无同类型同靶点产品获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2619459308","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619459308?lang=zh_cn&edition=full","pubTime":"2026-03-16 17:44","pubTimestamp":1773654296,"startTime":"0","endTime":"0","summary":"智通财经APP讯，福元医药(601089.SH)发布公告，近日，公司收到了国家药品监督管理局(以下简称“国家药监局”)核准签发关于FY103注射液的《药物临床试验批准通知书》，将于近期开展临床试验。FY103注射液为公司自主研发的化学药品1类创新药，适用于高血压的治疗，给药途径为皮下注射，目前国内外尚无同类型同靶点产品获批上市。截至目前，FY103注射液相关项目累计研发投入约人民币2,949.49万元(未经审计)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414349.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"福元医药(601089.SH)：FY103注射液药物临床试验获批 目前国内外尚无同类型同靶点产品获批上市","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601089","BK0239"],"gpt_icon":0},{"id":"2619459894","title":"福元医药(601089.SH)：双氯芬酸钠双释放肠溶胶囊获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2619459894","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619459894?lang=zh_cn&edition=full","pubTime":"2026-03-16 17:40","pubTimestamp":1773654003,"startTime":"0","endTime":"0","summary":"智通财经APP讯，福元医药 发布公告，近日，公司收到了国家药品监督管理局颁发的双氯芬酸钠双释放肠溶胶囊《药品注册证书》，批准该药品生产。据悉，由Aenova 研制的双氯芬酸钠双释放肠溶胶囊，于1984年8月获德国批准上市，1997年12月，经国家药品监督管理局批准，双氯芬酸钠双释放肠溶胶囊75mg在国内上市，2024年4月双氯芬酸钠双释放肠溶胶囊100mg在国内上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414348.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"福元医药(601089.SH)：双氯芬酸钠双释放肠溶胶囊获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","601089"],"gpt_icon":0},{"id":"2619841485","title":"福元医药公布国际专利申请：“用于抑制INHBE基因表达的双链核糖核酸及其修饰物、缀合物和用途”","url":"https://stock-news.laohu8.com/highlight/detail?id=2619841485","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619841485?lang=zh_cn&edition=full","pubTime":"2026-03-16 05:02","pubTimestamp":1773608543,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示福元医药（601089）公布了一项国际专利申请，专利名为“用于抑制INHBE基因表达的双链核糖核酸及其修饰物、缀合物和用途”，专利申请号为PCT/CN2025/125277，国际公布日为2026年3月12日。专利详情如下：图片来源：世界知识产权组织（WIPO）今年以来福元医药已公布的国际专利申请2个，较去年同期增加了100%。结合公司2025年中报财务数据，2025上半年公司在研发方面投入了1.66亿元，同比减12.54%。数据来源：企查查以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600001465.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601089","BK0239"],"gpt_icon":0},{"id":"2619178220","title":"每周股票复盘：福元医药（601089）FY101注射液I期临床效果达预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2619178220","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619178220?lang=zh_cn&edition=full","pubTime":"2026-03-15 03:13","pubTimestamp":1773515589,"startTime":"0","endTime":"0","summary":"截至2026年3月13日收盘，福元医药报收于23.02元，较上周的23.85元下跌3.48%。本周，福元医药3月10日盘中最高价报24.44元。本周关注点来自机构调研要点：FY101注射液I期临床效果达到公司预期。答：公司FY101注射液于2025年4月获批药物临床试验申请，正在按计划进行I期临床实验，目前获得的I期临床效果达到公司预期。答：FY101注射液的具体给药周期尚需根据I期临床试验的阶段性结果，结合后续II期临床试验方案进一步确定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031500000972.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601089","BK0239"],"gpt_icon":0},{"id":"2618180199","title":"福元医药：太平洋证券、银河基金等多家机构于3月6日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2618180199","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618180199?lang=zh_cn&edition=full","pubTime":"2026-03-12 17:30","pubTimestamp":1773307848,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年3月12日福元医药发布公告称太平洋证券周豫 戎晓婕、银河基金方伟 毛泓洋 秦娟娟、天风证券刘一伯 俞馨于2026年3月6日调研我司。具体内容如下：问：请介绍下公司FY101注射液的具体进展情况，公司计划何时披露其相关数据。答：公司FY101注射液于2025年4月获批药物临床试验申请，正在按计划进行I期临床实验，目前获得的I期临床效果达到公司预期。该股最近90天内共有1家机构给出评级，买入评级1家。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031200030300.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","601099","BK0201","BK0028","BK0077","BK0239","161027","601089","BK0012","BK0188","BK0276"],"gpt_icon":0},{"id":"2616890913","title":"福元医药(601089.SH)获得艾拉莫德化学原料药上市申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2616890913","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616890913?lang=zh_cn&edition=full","pubTime":"2026-03-02 16:17","pubTimestamp":1772439475,"startTime":"0","endTime":"0","summary":"智通财经APP讯，福元医药(601089.SH)发布公告，近日，公司收到国家药品监督管理局核准签发的艾拉莫德原料药《化学原料药上市申请批准通知书》，药品通用名称：艾拉莫德。艾拉莫德用于治疗活动性类风湿关节炎。公司本次取得艾拉莫德原料药《化学原料药上市申请批准通知书》，将进一步丰富公司产品线，促进公司持续、稳定、健康地发展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1408957.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"福元医药(601089.SH)获得艾拉莫德化学原料药上市申请批准通知书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","601089"],"gpt_icon":0},{"id":"2610813249","title":"福元医药(601089.SH)参与国家组织集采药品协议期满品种接续采购拟中选","url":"https://stock-news.laohu8.com/highlight/detail?id=2610813249","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610813249?lang=zh_cn&edition=full","pubTime":"2026-02-11 15:53","pubTimestamp":1770796403,"startTime":"0","endTime":"0","summary":"根据接续采购办公室于2026年2月10日发布的《国家组织集采药品协议期满品种接续采购拟中选结果公示》，公司包括依折麦布片在内的部分药品拟中选本次接续采购。本次接续采购是国家组织集采药品协议期满品种接续采购，中选结果预计于2026年3月底落地实施，即各省医疗机构开始按中选结果与厂家签署采购合同，并按滚动年进行采购。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404131.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601089","BK0239"],"gpt_icon":0},{"id":"2610614576","title":"福元医药(601089.SH)：盐酸溴己新口服溶液获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2610614576","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610614576?lang=zh_cn&edition=full","pubTime":"2026-02-10 15:53","pubTimestamp":1770709990,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 福元医药(601089.SH)发布公告，近日，公司全资子公司福元药业有限公司(以下简称“安徽福元”)收到了国家药品监督管理局(以下简称“国家药监局”)颁发的盐酸溴己新口服溶液(规格：200ml:160mg)(以下简称“该药品”)《药品注册证书》(证书编号：2026S00394)，批准该药品生产。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403638.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"福元医药(601089.SH)：盐酸溴己新口服溶液获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601089","BK0239"],"gpt_icon":0},{"id":"2610506382","title":"股市必读：福元医药（601089）2月6日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2610506382","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610506382?lang=zh_cn&edition=full","pubTime":"2026-02-09 08:10","pubTimestamp":1770595859,"startTime":"0","endTime":"0","summary":"来自机构调研要点：公司于2025年12月申报IND的FY103注射液已获临床试验申请受理。目前进展最快的研发管线正处于I期临床试验阶段。公司重视投资者回报，上市以来坚持年度现金分红，累计达6.6亿元。本次续标已完成报量，将于2月9日正式报价，公司将持续关注相关进展。根据2025年4月1日披露的2024年年报，公司药品制剂毛利率为68.36%，医疗器械毛利率为47.78%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260209/32006460.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["601089","BK0239"],"gpt_icon":0},{"id":"2610505474","title":"【私募调研记录】彤源投资调研福元医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2610505474","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610505474?lang=zh_cn&edition=full","pubTime":"2026-02-09 08:00","pubTimestamp":1770595253,"startTime":"0","endTime":"0","summary":"根据市场公开信息及2月6日披露的机构调研信息，知名私募彤源投资近期对1家上市公司进行了调研，相关名单如下：1）福元医药 调研纪要：公司创新药主要聚焦小核酸及小核酸递送系统研发，已搭建N-ER平台，进展最快管线处于I期临床。FY101注射液I期临床效果达预期，FY103注射液于2025年年末获临床试验申请受理。2025年2月4日完成1200万股股份回购用于股权激励，上市以来累计现金分红6.6亿元。2024年药品制剂毛利率为68.36%，医疗器械毛利率为47.78%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2026020900001184.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601089","BK0239"],"gpt_icon":0},{"id":"2609254445","title":"每周股票复盘：福元医药（601089）创新药FY101进入I期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2609254445","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609254445?lang=zh_cn&edition=full","pubTime":"2026-02-08 02:18","pubTimestamp":1770488293,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘，福元医药报收于26.6元，较上周的28.9元下跌7.96%。本周，福元医药2月2日盘中最高价报28.77元。本周关注点来自机构调研要点：公司创新药FY101注射液正在按计划进行I期临床实验。来自机构调研要点：公司自主研发新药FY103注射液已获境内临床试验申请受理。小核酸是继小分子和抗体后的第三大类药物，福元医药创新药主要聚焦小核酸及小核酸递送系统的研发。截至目前进展最快的管线在进行I期临床实验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800000679.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601089","159992","BK1161","06978","BK1574","BK0239"],"gpt_icon":0},{"id":"2609561604","title":"福元医药：有知名机构彤源投资参与的多家机构于2月5日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2609561604","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609561604?lang=zh_cn&edition=full","pubTime":"2026-02-06 18:01","pubTimestamp":1770372111,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年2月6日福元医药发布公告称彤源投资张翀翯、东吴证券刘若彤于2026年2月5日调研我司。小核酸是继小分子和抗体后的第三大类药物，福元医药创新药主要聚焦小核酸及小核酸递送系统的研发。截至目前进展最快的管线在进行I期临床实验。目前，此次续标已完成报量，将于2月9日正式报价，公司会对此事项保持关注。福元医药主营业务：药品制剂及医疗器械的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600030677.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","601089"],"gpt_icon":0},{"id":"2608891707","title":"股市必读：福元医药（601089）2月2日收盘跌9.93%，主力净流出332.16万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608891707","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608891707?lang=zh_cn&edition=full","pubTime":"2026-02-03 02:30","pubTimestamp":1770057032,"startTime":"0","endTime":"0","summary":"截至2026年2月2日收盘，福元医药报收于26.03元，下跌9.93%，换手率2.1%，成交量10.06万手，成交额2.73亿元。当日关注点来自交易信息汇总：福元医药2月2日收盘报26.03元，跌9.93%，主力资金当日净流出332.16万元。前10个交易日中，主力资金累计净流出5483.67万元，期间股价累计下跌5.51%。2月2日资金流向显示：主力资金净流出332.16万元，占总成交额1.22%；游资资金净流入2231.2万元，占总成交额8.18%；散户资金净流出1899.04万元，占总成交额6.97%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300001516.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601089","BK0239"],"gpt_icon":0},{"id":"2608070826","title":"每周股票复盘：福元医药（601089）FY101临床进展符合预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2608070826","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608070826?lang=zh_cn&edition=full","pubTime":"2026-02-01 03:47","pubTimestamp":1769888829,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，福元医药报收于28.9元，较上周的27.08元上涨6.72%。本周，福元医药1月30日盘中最高价报28.98元。本周关注点来自机构调研要点：FY101 I期临床效果达到公司预期。截至目前进展最快的管线在进行I期临床实验。答：目前FY101获得的I期临床效果达到公司预期，公司会根据项目进展与信息披露要求及时披露该项目进展情况，请届时关注公司公告。公司积极拥抱国家政策，截至目前共有18个品种集采中标。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100001319.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601089","BK0239"],"gpt_icon":0},{"id":"2607036209","title":"福元医药（601089）披露关于变更签字会计师的公告，1月29日股价下跌2.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607036209","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607036209?lang=zh_cn&edition=full","pubTime":"2026-01-29 23:00","pubTimestamp":1769698847,"startTime":"0","endTime":"0","summary":"截至2026年1月29日收盘，福元医药报收于27.24元，较前一交易日下跌2.58%，最新总市值为130.75亿元。近日，北京福元医药股份有限公司发布公告称，因天健会计师事务所工作安排变动，原委派的签字注册会计师朱俊杰先生变更为简艳会女士，现由廖屹峰先生、简艳会女士担任公司2025年度财务报表及内部控制审计报告的签字注册会计师。简艳会女士自2016年起成为中国注册会计师并执业，具备专业胜任能力，近三年未因执业行为受到处罚，且符合独立性要求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900044111.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","601089"],"gpt_icon":0},{"id":"2607673707","title":"福元医药：中金资管、淡水泉基金等多家机构于1月28日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2607673707","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607673707?lang=zh_cn&edition=full","pubTime":"2026-01-29 17:33","pubTimestamp":1769679216,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年1月29日福元医药发布公告称中金资管谢嘉豪、淡水泉基金刘潇于2026年1月28日调研我司。截至目前进展最快的管线在进行I期临床实验。公司积极拥抱国家政策，截至目前共有18个品种集采中标。关于本次活动是否涉及应披露重大信息的说明附件清单（如有）日期否2026年1月28日福元医药主营业务：药品制剂及医疗器械的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900029449.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","601089"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1774328484002,"stockEarnings":[{"period":"1week","weight":-0.0725},{"period":"1month","weight":-0.1526},{"period":"3month","weight":-0.1178},{"period":"6month","weight":-0.0781},{"period":"1year","weight":0.4111},{"period":"ytd","weight":-0.1046}],"compareEarnings":[{"period":"1week","weight":-0.0665},{"period":"1month","weight":-0.0658},{"period":"3month","weight":-0.0272},{"period":"6month","weight":-0.0105},{"period":"1year","weight":0.1333},{"period":"ytd","weight":-0.0392}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京福元医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"22691人(较上一季度减少3.39%)","perCapita":"21153股","listingDate":"2022-06-30","address":"北京市通州区通州工业开发区广源东街8号","registeredCapital":"48000万元","survey":" 北京福元医药股份有限公司的主营业务是药品制剂及医疗器械的研发、生产和销售。公司的主要产品是心血管系统类、慢性肾病类、皮肤病类、消化系统类、糖尿病类、精神神经系统类、妇科类、一次性使用吸氧管。公司已入选北京医药产业跨越发展工程G20企业，荣列中国药品研发综合实力百强榜。","listedPrice":14.62},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"福元医药(601089)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供福元医药(601089)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"福元医药,601089,福元医药股票,福元医药股票老虎,福元医药股票老虎国际,福元医药行情,福元医药股票行情,福元医药股价,福元医药股市,福元医药股票价格,福元医药股票交易,福元医药股票购买,福元医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"福元医药(601089)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供福元医药(601089)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}